

If further election is required, applicants would then elect anhydrous mometasone furoate as the corticosteroid and pirbuterol acetate as the bronchodilator, in which case the claims reading on the elected species are 51-80, 84-87, 89-100 and 102-116.

Applicants respectfully remind the Examiner that this election of species is for the sole purpose of the Examiner's initial search and examination, and that upon allowance of a generic claim, applicants will be entitled to have all non-elected species encompassed by that claim examined (37 C.F.R. § 1.141).

CLAIMS:

Claims 51-54 have been amended and new claims 75-116 have been added in order to more particularly point out and distinctly claim that which applicants regard as the invention.

In claim 51, the original recitation of the "optional" carrier has been deleted, and the possibility that the formulation includes the carrier is now recited in dependent claim 87. Accordingly, claim 51 has not been changed in substance or scope. Claims 52-54 have been amended solely for clarification.

New claims 75-86 and 88-116 substantially correspond to now-canceled claims 1-50 and 56-74,
and accordingly do not introduce any new matter.

If the Examiner has any questions concerning this communication, or would like to discuss the application, the art, or other pertinent matters, he is welcome to contact the undersigned attorney at (650) 330-0900.

Respectfully submitted,

By:



Dianne E. Reed
Registration No. 31,292

REED & ASSOCIATES
800 Menlo Avenue, Suite 210
Menlo Park, California 94025
(650) 330-0900 Telephone
(650) 330-0980 Facsimile